<DOC>
	<DOCNO>NCT01172496</DOCNO>
	<brief_summary>This single center , open label , randomize , two-period , two-sequence cross-over study design evaluate relative bioavailability treprostinil diethanolamine 1 mg tablet reference treprostinil diethanolamine 1 mg oral solution ( administer four 0.25 mg dos every 2 hour 1 mg total dose ) twenty-four healthy volunteer . Other secondary outcome interest include assessment pharmacokinetic parameter treprostinil diethanolamine 1 mg tablet treprostinil diethanolamine 1 mg oral solution administer four dos ( 0.25 mg every 2 hour 1 mg total dose ) evaluation safety tolerability treatment regimen .</brief_summary>
	<brief_title>A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets Oral Solution Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Subject healthy age 1855 year age Female subject must weigh 55 100 kg , BMI 19.029.9. kg/m2 ; inclusive screening . Male subject must weigh 55 120 kg , BMI 19.032.0 kg/m2 ; inclusive screening . Subject medical history , physical examination , vital sign , ECG clinical laboratory result within normal limit consider clinically significant Investigator Screening . Female subject childbearing potential practice abstinence effective birth control method time provide write informed consent end study . Effective birth control define intrauterine device ( IUD ) , barrier method preferably combination spermicidal foam suppository , use oral , transdermal intravaginal hormonal contraceptive . Subject agree abstain take prescription medication ( except contraceptive ) 14 day prior start study procedure abstain take nonprescription medication ( except multivitamin ) herbal supplement 7 day prior begin study procedure discharge study ( unless prescribe Investigator treat AE ) . Subject agree abstain consume alcohol 3 day prior begin study procedure discharge study . Subject agree abstain consume grapefruit xanthinecontaining food beverage 3 day prior begin study procedure discharge study . Subject agree refrain strenuous exercise begin study procedure discharge study . Subject able communicate effectively study personnel consider reliable , willing cooperative term compliance protocol requirement . Subject clinically relevant abnormality identify screen physical examination , 12lead ECG , laboratory examination . Subject history anaphylaxis , previous document hypersensitivity reaction , clinically significant idiosyncratic reaction drug . Subject clinically significant history neurological , cardiovascular , respiratory , endocrine , hematological , hepatic , renal , gastrointestinal , genitourinary , pulmonary , and/or musculoskeletal disease ; glaucoma ; psychiatric disorder , chronic disease , whether control medication . The subject history postural hypotension , unexplained syncope , blood pressure le 85 mmHg systolic 50 mmHg diastolic , pulse rate great 90 bpm sit rest 5 minute Screening Baseline . Subject predispose condition could interfere absorption , distribution , metabolism , excretion drug . Subject test positive screen visit HIV infection , HBsAg , HCV antibody . Subject pregnant lactating . Subject currently use tobacco product history tobacco use within six month prior Period 1 . Subject history alcohol abuse history current impairment organ function reasonably related alcohol abuse . Subject history current evidence abuse licit illicit drug positive urine screen drug abuse . Subject history abnormal bleeding tendency . Subject donate blood plasma lose significant volume blood ( great 450 mL ) within four week prior Period 1 . Subject participate investigational drug study within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>